Patients On Pfizer’s initiative to return clinical trial data to pati... Among the most common reasons for dropping out, patients cite a lack of communication about the trial
R&D Focus on the positive to stop public perception being a barr... Public misconceptions surrounding the process, its risks and its benefits remain a significant barrier to clinical trial participation, which is not surprising in a world where the only int
Oncology Hernexeos and what’s next, with Vicky Brown At Reuters Pharma USA this week, Boehringer Ingelheim's Vicky Brown spoke with us about the company's recent approval for Hernexeos in NSCLC.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
